433 related articles for article (PubMed ID: 17332359)
1. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
2. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
3. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
Meyers S; Lenny N; Sun W; Hiebert SW
Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
[TBL] [Abstract][Full Text] [Related]
4. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein.
Yang G; Thompson MA; Brandt SJ; Hiebert SW
Oncogene; 2007 Jan; 26(1):91-101. PubMed ID: 16799637
[TBL] [Abstract][Full Text] [Related]
6. MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21).
Kozu T; Fukuyama T; Yamami T; Akagi K; Kaneko Y
Genes Chromosomes Cancer; 2005 May; 43(1):45-53. PubMed ID: 15723339
[TBL] [Abstract][Full Text] [Related]
7. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
8. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
9. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
10. Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.
Wichmann C; Grez M; Lausen J
Curr Drug Targets; 2010 Sep; 11(9):1181-91. PubMed ID: 20583973
[TBL] [Abstract][Full Text] [Related]
11. Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?
Deluche L; Joha S; Corm S; Daudignon A; Geffroy S; Quief S; Villenet C; Kerckaert JP; Laï JL; Preudhomme C; Roche-Lestienne C
Genes Chromosomes Cancer; 2008 Dec; 47(12):1110-7. PubMed ID: 18767145
[TBL] [Abstract][Full Text] [Related]
12. Functional domains of the t(8;21) fusion protein, AML-1/ETO.
Lenny N; Meyers S; Hiebert SW
Oncogene; 1995 Nov; 11(9):1761-9. PubMed ID: 7478604
[TBL] [Abstract][Full Text] [Related]
13. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
Barseguian K; Lutterbach B; Hiebert SW; Nickerson J; Lian JB; Stein JL; van Wijnen AJ; Stein GS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15434-9. PubMed ID: 12427969
[TBL] [Abstract][Full Text] [Related]
14. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells.
Li X; Xu YB; Wang Q; Lu Y; Zheng Y; Wang YC; Lübbert M; Zhao KW; Chen GQ
J Cell Physiol; 2006 Sep; 208(3):594-601. PubMed ID: 16741927
[TBL] [Abstract][Full Text] [Related]
15. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.
Liu Y; Cheney MD; Gaudet JJ; Chruszcz M; Lukasik SM; Sugiyama D; Lary J; Cole J; Dauter Z; Minor W; Speck NA; Bushweller JH
Cancer Cell; 2006 Apr; 9(4):249-60. PubMed ID: 16616331
[TBL] [Abstract][Full Text] [Related]
16. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
[TBL] [Abstract][Full Text] [Related]
17. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
[TBL] [Abstract][Full Text] [Related]
18. The 8;21 translocation in leukemogenesis.
Peterson LF; Zhang DE
Oncogene; 2004 May; 23(24):4255-62. PubMed ID: 15156181
[TBL] [Abstract][Full Text] [Related]
19. Nuclear import and subnuclear localization of the proto-oncoprotein ETO (MTG8).
Odaka Y; Mally A; Elliott LT; Meyers S
Oncogene; 2000 Jul; 19(32):3584-97. PubMed ID: 10951564
[TBL] [Abstract][Full Text] [Related]
20. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
